The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new chemical synthesis route.

The present invention relates to a process for preparing aldehydes and ketones by carbon-carbon bond cleavage of alkenes, wherein the process is catalysed by first row transition metal nitro coordinated polyoxometalate catalyst. The catalyst can be prepared by pre-treatment of aqua coordinated polyoxometalates with NO.sub.2, or they are formed in situ when the reactions are carried in nitroalkanes under aerobic conditions, or they are formed in situ from nitrosyl (NO) compounds in the presence of O.sub.2.

The present invention relates to a process for preparing aldehydes and ketones by carbon-carbon bond cleavage of alkenes, wherein the process is catalysed by first row transition metal nitro coordinated polyoxometalate catalyst. The catalyst can be prepared by pre-treatment of aqua coordinated polyoxometalates with NO.sub.2, or they are formed in situ when the reactions are carried in nitroalkanes under aerobic conditions, or they are formed in situ from nitrosyl (NO) compounds in the presence of O.sub.2.

Compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite;
under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.

This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite;
under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.